JAZZ - Jazz Pharmaceuticals announces significant new investment in UK manufacturing
Jazz Pharmaceuticals (NASDAQ:JAZZ) and its subsidiary, GW Pharmaceuticals (OTCPK:GWPRF) announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne. The construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines. This represents a significant commitment to the UK by GW Pharmaceuticals (GWPRF), now part of Jazz Pharmaceuticals (JAZZ), investing $100M (£75m) and creating more than 100 highly skilled jobs.
For further details see:
Jazz Pharmaceuticals announces significant new investment in UK manufacturing